Methylprednisolone hemisuccinate
- Generic Name
- Methylprednisolone hemisuccinate
- Brand Names
- Solu-medrol
- Drug Type
- Small Molecule
- Chemical Formula
- C26H34O8
- CAS Number
- 2921-57-5
- Unique Ingredient Identifier
- 5GMR90S4KN
- Background
A water-soluble ester of methylprednisolone used for cardiac, allergic, and hypoxic emergencies.
- Associated Conditions
- Acute Gouty Arthritis, Ankylosing Spondylitis (AS), Berylliosis, Congenital Adrenal Hyperplasia (CAH), Congenital Hypoplastic Anemia, Dermatitis bullous, Dermatomyositis (DM), Edema of the cerebrum, Hypercalcemia of Malignancy, Immune Thrombocytopenia (ITP), Leukemias, Lymphoma, Multiple sclerosis exacerbation, Mycosis Fungoides (MF), Ophthalmia, Sympathetic, Pemphigus, Polymyositis, Primary adrenocortical insufficiency, Psoriatic Arthritis, Pure Red Cell Aplasia, Refractory Uveitis, Regional Enteritis, Rheumatoid Arthritis, Secondary adrenocortical insufficiency, Secondary thrombocytopenia, Stevens-Johnson Syndrome, Systemic Lupus Erythematosus, Temporal Arteritis, Trichinosis, Tuberculous Meningitis, Ulcerative Colitis, Acquired immune hemolytic anemia, Acute rheumatic carditis, Disseminated Pulmonary Tuberculosis (TB), Exfoliative erythroderma, Fulminating Pulmonary Tuberculosis, Idiopathic eosinophilic pneumonias, Non-suppurative Thyroiditis, Severe Allergic Reactions, Symptomatic Sarcoidosis
- Associated Therapies
- Palliative Treatment
A Comparative Study of Glucocorticoids Efficacy in Acute Respiratory Distress Syndrome
Phase 2
Recruiting
- Conditions
- Acute Respiratory Distress Syndrome
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2025-01-06
- Lead Sponsor
- Fayoum University
- Target Recruit Count
- 300
- Registration Number
- NCT06496997
- Locations
- 🇪🇬
Fayoum University, Fayoum, Egypt
FcRn Antagonists (Efgartigimod) for Acute NMOSD Attack
Phase 2
Not yet recruiting
- Conditions
- NMO Spectrum DisorderNeuromyelitis Optica Spectrum DisorderNeuromyelitis Optica
- Interventions
- First Posted Date
- 2024-07-11
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Tianjin Medical University General Hospital
- Target Recruit Count
- 63
- Registration Number
- NCT06497374
The Effect of a Methylprednisolone Taper on Outcomes Following Total Knee Arthroplasty
Phase 4
Not yet recruiting
- Conditions
- Arthritis KneeKnee OsteoarthritisPain, Postoperative
- Interventions
- First Posted Date
- 2024-07-08
- Last Posted Date
- 2025-04-15
- Lead Sponsor
- F. Johannes Plate
- Target Recruit Count
- 100
- Registration Number
- NCT06489626
- Locations
- 🇺🇸
UPMC East, Monroeville, Pennsylvania, United States
🇺🇸UPMC Shadyside Hospital, Pittsburgh, Pennsylvania, United States
TACKLE-IT Trial - Treat Acute T Cell Rejection With Evidence and Confidence in Kidney Transplant Recipients
Phase 4
Not yet recruiting
- Conditions
- Rejection; Transplant, PancreasRejection; Transplant, Kidney
- Interventions
- First Posted Date
- 2024-06-25
- Last Posted Date
- 2024-06-25
- Lead Sponsor
- University of Sydney
- Target Recruit Count
- 540
- Registration Number
- NCT06474273
- Locations
- 🇨🇦
Transplant Manitoba, adult, Winnipeg, Manitoba, Canada
🇦🇺Royal Adelaide Hospital, Adelaide, South Australia, Australia
🇦🇺Queensland Children's Hospital, South Brisbane, Queensland, Australia
Comparative Effects of Methylprednisolone and Prednisolone on the Risk of Acute Decompensated Heart Failure - An Emulated Target Trial
- First Posted Date
- 2024-06-21
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Diakonhjemmet Hospital
- Target Recruit Count
- 12000
- Registration Number
- NCT06468007
Localized Injection of Lidocaine and Glucocorticoid for Headache Treatment
Phase 2
Not yet recruiting
- Conditions
- Refractory Migraine
- Interventions
- First Posted Date
- 2024-06-17
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- The Cooper Health System
- Target Recruit Count
- 230
- Registration Number
- NCT06462781
- Locations
- 🇺🇸
Cooper University Health Care, Camden, New Jersey, United States
Early Immunotherapy with Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients with Anti-Hu-associated Paraneoplastic Sensory Neuronopathy
Phase 2
Recruiting
- Conditions
- Paraneoplastic Sensory Neuronopathy
- Interventions
- First Posted Date
- 2024-04-18
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Assistance Publique - Hôpitaux de Paris
- Target Recruit Count
- 21
- Registration Number
- NCT06373211
- Locations
- 🇫🇷
Hôpital Pitié-Salpêtrière, Paris, France
Methylprednisolone Adjunctive to Endovascular Treatment for Stroke
Phase 3
Not yet recruiting
- Conditions
- Acute Ischemic Stroke
- Interventions
- Drug: Placebo (Methylprednisolone sodium succinate simulant)
- First Posted Date
- 2024-04-11
- Last Posted Date
- 2024-04-11
- Lead Sponsor
- Wan-Jin Chen
- Target Recruit Count
- 735
- Registration Number
- NCT06360458
- Locations
- 🇨🇳
Department of Neurology, First Affiliated Hospital Fujian Medical University, Fuzhou, Fujian, China
A Study to Investigate Subcutaneous Isatuximab in Combination With Weekly Carfilzomib and Dexamethasone in Adult Participants With Relapsed and/or Refractory Multiple Myeloma
Phase 2
Recruiting
- Conditions
- Plasma Cell Myeloma Refractory
- Interventions
- First Posted Date
- 2024-04-10
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 64
- Registration Number
- NCT06356571
- Locations
- 🇺🇸
Smilow Cancer Center at Yale-New Haven- Site Number : 8400020, New Haven, Connecticut, United States
🇺🇸Millennium Oncology- Site Number : 8400011, Pembroke Pines, Florida, United States
🇺🇸BRCR Global- Site Number : 8400008, Plantation, Florida, United States
Testing the Addition of the Anti-cancer Drug Venetoclax and/or the Anti-cancer Immunotherapy Blinatumomab to the Usual Chemotherapy Treatment for Infants With Newly Diagnosed KMT2A-rearranged or KMT2A-non-rearranged Leukemia
Phase 2
Recruiting
- Conditions
- B Acute Lymphoblastic LeukemiaAcute Leukemia of Ambiguous Lineage
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: FDG-Positron Emission TomographyProcedure: Lumbar PunctureProcedure: Magnetic Resonance ImagingProcedure: Multigated Acquisition Scan
- First Posted Date
- 2024-03-19
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 153
- Registration Number
- NCT06317662
- Locations
- 🇺🇸
Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, United States
🇺🇸Albany Medical Center, Albany, New York, United States
🇺🇸University of Virginia Cancer Center, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath